Wesseling J - Search Results

1

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF, Rodenhuis S, Wesseling J. Lips EH, et al. Among authors: wesseling j. Breast Cancer Res Treat. 2013 Jul;140(1):63-71. doi: 10.1007/s10549-013-2620-0. Epub 2013 Jul 5. Breast Cancer Res Treat. 2013. PMID: 23828499 Free PMC article.

2

The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.

van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J. van der Vegt B, et al. Among authors: wesseling j. Histopathology. 2007 Sep;51(3):322-35. doi: 10.1111/j.1365-2559.2007.02757.x. Epub 2007 Jul 23. Histopathology. 2007. PMID: 17645748 Free article.

3

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC. Bueno-de-Mesquita JM, et al. Among authors: wesseling j. Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Lancet Oncol. 2007. PMID: 18042430

4

The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study.

Pengel KE, Loo CE, Teertstra HJ, Muller SH, Wesseling J, Peterse JL, Bartelink H, Rutgers EJ, Gilhuijs KG. Pengel KE, et al. Among authors: wesseling j. Breast Cancer Res Treat. 2009 Jul;116(1):161-9. doi: 10.1007/s10549-008-0182-3. Epub 2008 Sep 21. Breast Cancer Res Treat. 2009. PMID: 18807269 Clinical Trial.

5

Validation of 70-gene prognosis signature in node-negative breast cancer.

Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, van de Vijver MJ. Bueno-de-Mesquita JM, et al. Among authors: wesseling j. Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26. Breast Cancer Res Treat. 2009. PMID: 18819002

6

Microarray methods to identify factors determining breast cancer progression: potentials, limitations, and challenges.

van der Vegt B, de Bock GH, Hollema H, Wesseling J. van der Vegt B, et al. Among authors: wesseling j. Crit Rev Oncol Hematol. 2009 Apr;70(1):1-11. doi: 10.1016/j.critrevonc.2008.09.001. Epub 2008 Oct 9. Crit Rev Oncol Hematol. 2009. PMID: 18848465 Review.

7

Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer.

Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stål O, Landberg G, Linn SC. Holm C, et al. Among authors: wesseling j. J Pathol. 2009 Feb;217(3):372-9. doi: 10.1002/path.2455. J Pathol. 2009. PMID: 18991335

8

[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].

Straver ME, van Adrichem JC, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Gilhuijs KG, Oldenburg HS, Wesseling J, Russell NS, Antonini N, Vrancken Peeters MT. Straver ME, et al. Among authors: wesseling j. Ned Tijdschr Geneeskd. 2008 Nov 15;152(46):2519-25. Ned Tijdschr Geneeskd. 2008. PMID: 19055260 Dutch.

9

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.

Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, Vrancken Peeters MJ, van Tinteren H, Van't Veer LJ, Rodenhuis S. Straver ME, et al. Among authors: wesseling j. Breast Cancer Res Treat. 2010 Feb;119(3):551-8. doi: 10.1007/s10549-009-0333-1. Epub 2009 Feb 13. Breast Cancer Res Treat. 2010. PMID: 19214742

10

Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.

van der Vegt B, de Bock GH, Bart J, Zwartjes NG, Wesseling J. van der Vegt B, et al. Among authors: wesseling j. Mod Pathol. 2009 Jul;22(7):879-86. doi: 10.1038/modpathol.2009.37. Epub 2009 Mar 20. Mod Pathol. 2009. PMID: 19305385 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

371 results

Search Page